Two Sigma Securities LLC increased its position in Bristol-Myers Squibb Company (NYSE:BMY) by 88.5% during the first quarter, Holdings Channel reports. The firm owned 9,596 shares of the biopharmaceutical company’s stock after buying an additional 4,506 shares during the period. Two Sigma Securities LLC’s holdings in Bristol-Myers Squibb were worth $522,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in BMY. Dodge & Cox bought a new position in Bristol-Myers Squibb during the fourth quarter worth $1,316,815,000. Ameriprise Financial Inc. raised its position in Bristol-Myers Squibb by 18.7% in the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after buying an additional 2,451,390 shares during the period. Swiss National Bank raised its position in Bristol-Myers Squibb by 27.2% in the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after buying an additional 1,267,900 shares during the period. Karp Capital Management Corp bought a new position in Bristol-Myers Squibb during the first quarter worth $38,890,000. Finally, Canada Pension Plan Investment Board raised its position in Bristol-Myers Squibb by 23.8% in the first quarter. Canada Pension Plan Investment Board now owns 3,362,609 shares of the biopharmaceutical company’s stock worth $182,859,000 after buying an additional 646,000 shares during the period. 69.79% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Company (BMY) traded up 0.32% on Friday, hitting $56.77. The stock had a trading volume of 1,204,470 shares. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $61.30. The company’s 50 day moving average is $55.82 and its 200 day moving average is $54.60. The firm has a market cap of $93.10 billion, a PE ratio of 20.73 and a beta of 1.17.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. Bristol-Myers Squibb’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.69 earnings per share. On average, equities research analysts expect that Bristol-Myers Squibb Company will post $2.97 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were paid a $0.39 dividend. The ex-dividend date was Wednesday, July 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.76%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.

COPYRIGHT VIOLATION WARNING: “Two Sigma Securities LLC Buys 4,506 Shares of Bristol-Myers Squibb Company (NYSE:BMY)” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/11/two-sigma-securities-llc-buys-4506-shares-of-bristol-myers-squibb-company-nysebmy.html.

BMY has been the topic of a number of recent research reports. BMO Capital Markets lowered Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price objective on the stock. in a research note on Wednesday, May 3rd. Robert W. Baird started coverage on Bristol-Myers Squibb in a research note on Tuesday, April 25th. They set an “outperform” rating on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $64.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, June 5th. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price target on the stock in a research note on Monday, June 5th. Finally, BidaskClub lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, July 3rd. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $62.69.

In related news, Director Theodore R. Samuels II bought 6,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The stock was bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the purchase, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.23% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.